Randomized trial · people
Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In type 2 diabetes, adding cagrilintide to semaglutide gave more weight loss than either drug alone over 32 weeks, but its blood sugar edge over semaglutide alone was not clear.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 92
- Published
- 2023
- Journal
- Lancet
What they tested
The team tested how well and how safely weekly cagrilintide combined with weekly semaglutide (called CagriSema) controls blood sugar in type 2 diabetes, compared with each drug alone.
How the study was done
A randomized, double-blind phase 2 trial (neither participants nor investigators knew who got what) in 92 adults with type 2 diabetes and a BMI, a weight-for-height score, of 27 kg/m2 or higher, all on metformin with or without an SGLT2 inhibitor, at 17 US sites. For 32 weeks, each person got a weekly shot under the skin of the combination, semaglutide alone or cagrilintide alone, each raised to 2.4 mg.

Model. Individual results vary.
What they found
HbA1c, a 3-month average of blood sugar, changed by -2.2 percentage points with the combination, -1.8 with semaglutide and -0.9 with cagrilintide. The combination beat cagrilintide alone on HbA1c (difference -1.3 percentage points) but not semaglutide alone (p=0.075). Body weight changed by -15.6% with the combination, -5.1% with semaglutide and -8.1% with cagrilintide, so the combination beat both single drugs, and time with blood sugar in the 3.9-10.0 mmol/L range rose from 45.9% to 88.9% on the combination. Side effects were reported by 68%, 71% and 80% of each group, mostly mild or moderate stomach and gut effects, with no level 2 or 3 hypoglycemia (low blood sugar) and no deaths.
What it doesn’t show
This was a small, 32-week phase 2 trial with no placebo arm, run only in US adults already taking metformin. It was funded by Novo Nordisk.
The paper
Frias et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023.
The compounds
More studies on Cagrilintide
- CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeksRandomized trial · people · 2026
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3Randomized trial · people · 2026
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Randomized trial · people · 2025
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2Randomized trial · people · 2025
- Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20Randomized trial · people · 2021
- Every study on Cagrilintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.